Annual SG&A
$500.81 M
+$223.65 M+80.69%
31 December 2023
Summary:
Apellis Pharmaceuticals annual selling, general & administrative expenses is currently $500.81 million, with the most recent change of +$223.65 million (+80.69%) on 31 December 2023. During the last 3 years, it has risen by +$361.41 million (+259.26%). APLS annual SG&A is now at all-time high.APLS Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$121.98 M
-$6.10 M-4.76%
30 September 2024
Summary:
Apellis Pharmaceuticals quarterly selling, general & administrative expenses is currently $121.98 million, with the most recent change of -$6.10 million (-4.76%) on 30 September 2024. Over the past year, it has dropped by -$23.66 million (-16.25%). APLS quarterly SG&A is now -16.25% below its all-time high of $145.65 million, reached on 30 September 2023.APLS Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$11.68 B
-$250.10 M-2.19%
30 September 2024
Summary:
Apellis Pharmaceuticals TTM selling, general & administrative expenses is currently -$11.68 billion, with the most recent change of -$250.10 million (-2.19%) on 30 September 2024. Over the past year, it has dropped by -$12.13 billion (-2734.15%). APLS TTM SG&A is now -47354.93% below its all-time high of $544.93 million, reached on 30 June 2024.APLS TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APLS Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +80.7% | -16.3% | -2734.2% |
| 3 y3 years | +259.3% | +166.6% | -6597.2% |
| 5 y5 years | +2112.2% | +554.8% | -10000.0% |
APLS Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +259.3% | -16.3% | +194.2% | -141.3% | at low |
| 5 y | 5 years | at high | +2112.2% | -16.3% | +554.8% | -694.3% | at low |
| alltime | all time | at high | >+9999.0% | -16.3% | >+9999.0% | <-9999.0% | at low |
Apellis Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $121.98 M(-4.8%) | $521.27 M(-4.3%) |
| June 2024 | - | $128.08 M(-1.1%) | $544.93 M(+3.2%) |
| Mar 2024 | - | $129.50 M(-8.6%) | $528.23 M(+5.5%) |
| Dec 2023 | $500.81 M(+80.7%) | $141.70 M(-2.7%) | $500.81 M(+12.9%) |
| Sept 2023 | - | $145.65 M(+30.8%) | $443.48 M(+17.9%) |
| June 2023 | - | $111.37 M(+9.1%) | $376.24 M(+14.7%) |
| Mar 2023 | - | $102.09 M(+21.0%) | $328.07 M(+18.4%) |
| Dec 2022 | $277.16 M(+56.8%) | $84.37 M(+7.6%) | $277.16 M(+18.3%) |
| Sept 2022 | - | $78.41 M(+24.1%) | $234.26 M(+16.2%) |
| June 2022 | - | $63.20 M(+23.5%) | $201.62 M(+7.6%) |
| Mar 2022 | - | $51.19 M(+23.5%) | $187.38 M(+6.0%) |
| Dec 2021 | $176.77 M(+26.8%) | $41.46 M(-9.4%) | $176.77 M(-1.7%) |
| Sept 2021 | - | $45.76 M(-6.5%) | $179.80 M(+5.1%) |
| June 2021 | - | $48.97 M(+20.7%) | $171.03 M(+13.7%) |
| Mar 2021 | - | $40.58 M(-8.8%) | $150.48 M(+7.9%) |
| Dec 2020 | $139.40 M(+107.9%) | $44.49 M(+20.3%) | $139.40 M(+13.9%) |
| Sept 2020 | - | $36.99 M(+30.2%) | $122.38 M(+17.7%) |
| June 2020 | - | $28.41 M(-3.7%) | $104.02 M(+17.7%) |
| Mar 2020 | - | $29.50 M(+7.4%) | $88.38 M(+31.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $67.05 M(+196.2%) | $27.47 M(+47.4%) | $67.05 M(+45.9%) |
| Sept 2019 | - | $18.63 M(+45.8%) | $45.97 M(+36.8%) |
| June 2019 | - | $12.78 M(+56.4%) | $33.60 M(+25.5%) |
| Mar 2019 | - | $8.17 M(+27.9%) | $26.77 M(+18.3%) |
| Dec 2018 | $22.64 M(+116.4%) | $6.39 M(+2.0%) | $22.64 M(+7.3%) |
| Sept 2018 | - | $6.27 M(+5.3%) | $21.11 M(+24.8%) |
| June 2018 | - | $5.95 M(+47.4%) | $16.91 M(+33.4%) |
| Mar 2018 | - | $4.04 M(-17.0%) | $12.68 M(+21.2%) |
| Dec 2017 | $10.46 M(+143.1%) | $4.86 M(+134.6%) | $10.46 M(+56.4%) |
| Sept 2017 | - | $2.07 M(+21.1%) | $6.69 M(+19.1%) |
| June 2017 | - | $1.71 M(-6.1%) | $5.62 M(+43.8%) |
| Mar 2017 | - | $1.82 M(+67.5%) | $3.91 M(+87.3%) |
| Dec 2016 | $4.30 M(-32.3%) | $1.09 M(+8.7%) | $2.09 M(-48.4%) |
| Sept 2016 | - | $1.00 M(-67.1%) | $4.04 M(-9.3%) |
| Dec 2015 | $6.36 M(+118.6%) | $3.04 M(+115.3%) | $4.46 M(+82.7%) |
| Sept 2015 | - | $1.41 M(+37.8%) | $2.44 M(+43.8%) |
| Dec 2014 | $2.91 M(+70.5%) | $1.03 M(+53.1%) | $1.70 M(+153.1%) |
| Sept 2014 | - | $669.70 K | $669.70 K |
| Dec 2013 | $1.71 M | - | - |
FAQ
- What is Apellis Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual SG&A year-on-year change?
- What is Apellis Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly SG&A year-on-year change?
- What is Apellis Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM SG&A year-on-year change?
What is Apellis Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of APLS is $500.81 M
What is the all time high annual SG&A for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual selling, general & administrative expenses is $500.81 M
What is Apellis Pharmaceuticals annual SG&A year-on-year change?
Over the past year, APLS annual selling, general & administrative expenses has changed by +$223.65 M (+80.69%)
What is Apellis Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of APLS is $121.98 M
What is the all time high quarterly SG&A for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $145.65 M
What is Apellis Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, APLS quarterly selling, general & administrative expenses has changed by -$23.66 M (-16.25%)
What is Apellis Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of APLS is -$11.68 B
What is the all time high TTM SG&A for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM selling, general & administrative expenses is $544.93 M
What is Apellis Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, APLS TTM selling, general & administrative expenses has changed by -$12.13 B (-2734.15%)